Kwality Pharma Peer Comparison
BSE: 539997
₹3,752.80
₹-92.10
(-2.40%)
As on 22-Sep-2026 15:29IST
Market cap
₹3,855 Cr
Revenue (TTM)
₹554 Cr
P/E Ratio
47.6
P/B Ratio
10.8
Div. Yield
0 %
Edit
| Kwality Pharma | Caplin Point Lab | Shilpa Medicare | Eris Lifesciences | Pfizer | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
3,855 | 21,264 | 20,418 | 17,600 | 18,400 |
Revenue (₹ Cr) |
554 | 2,287 | 1,682 | 3,230 | 2,570 |
Net Profit (₹ Cr) |
81.04 | 678.07 | 273.51 | 666.92 | 735.15 |
Net Margin (%) |
14.55 | 28.10 | 16.19 | 20.60 | 26.88 |
RoE (%) |
26.26 | 19.73 | 11.15 | 18.75 | 19.16 |
Price to Earnings |
47.56 | 31.96 | 68.67 | 27.33 | 25.03 |
Price-To-Book |
10.82 | 5.79 | 7.60 | 4.36 | 4.17 |
Income Statement (₹ Cr)
| Kwality Pharma | Caplin Point Lab | Shilpa Medicare | Eris Lifesciences | Pfizer | |
|---|---|---|---|---|---|
|
Operating Revenue
|
553.96 | 2,287.33 | 1,682.47 | 3,229.67 | 2,569.77 |
|
Total Income
|
557.06 | 2,413.29 | 1,689.83 | 3,237.12 | 2,735.39 |
|
Total Expenditure
|
418.87 | 1,490.75 | 1,203.91 | 2,090.06 | 1,628.14 |
|
EBITDA
|
135.08 | 796.58 | 478.55 | 1,139.61 | 941.63 |
|
Depreciation
|
20.04 | 78.10 | 126.01 | 281.06 | 57.58 |
|
EBIT
|
115.04 | 718.48 | 352.55 | 858.55 | 884.05 |
|
Interest
|
10.87 | 0.88 | 52.11 | 190.64 | 7.69 |
|
Other Income
|
3.11 | 125.96 | 7.37 | 7.45 | 165.62 |
|
Exceptional Items
|
-0.83 | 0.00 | 12.16 | -17.24 | -49.16 |
|
Profit before Tax
|
106.45 | 843.56 | 319.96 | 658.12 | 992.82 |
|
Provision for Tax
|
25.40 | 165.49 | 46.45 | -8.80 | 257.67 |
|
Profit after Tax
|
81.04 | 678.07 | 273.51 | 666.92 | 735.15 |
Liabilities (₹ Cr)
| Kwality Pharma | Caplin Point Lab | Shilpa Medicare | Eris Lifesciences | Pfizer | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
331.60 | 3,586.42 | 2,591.20 | 3,902.67 | 4,202.90 |
|
Minority Interest
|
0.00 | -12.71 | 0.00 | -21.81 | 0.00 |
|
Non-Current Liabilities
|
36.77 | 28.74 | 266.35 | 1,392.75 | 91.50 |
|
Current Liabilities
|
225.52 | 385.94 | 848.06 | 2,077.10 | 627.48 |
|
Total Liabilities
|
592.21 | 4,037.51 | 3,705.61 | 7,246.72 | 4,921.88 |
Assets (₹ Cr)
| Kwality Pharma | Caplin Point Lab | Shilpa Medicare | Eris Lifesciences | Pfizer | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
175.08 | 1,291.22 | 2,525.44 | 5,617.77 | 770.28 |
|
Current Assets
|
405.68 | 2,585.66 | 1,109.77 | 1,539.85 | 3,803.22 |
|
Total Assets
|
592.21 | 4,037.51 | 3,705.61 | 7,246.72 | 4,921.88 |
|
Total Debt*
|
130.46 | 0.57 | 657.97 | 2,309.68 | 2.50 |
|
Net Current Assets
|
180.16 | 2,199.72 | 261.71 | -537.25 | 3,175.74 |
|
Contingent Liabilities
|
36.98 | 17.53 | 160.01 | 51.57 | 370.49 |
Cashflow (₹ Cr)
| Kwality Pharma | Caplin Point Lab | Shilpa Medicare | Eris Lifesciences | Pfizer | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
16.59 | 523.24 | 342.18 | 537.99 | 967.57 |
|
Cash Flow from Investing Activities
|
-34.91 | -582.30 | -325.92 | -369.46 | -561.67 |
|
Cash from Financing Activities
|
7.04 | -46.46 | 13.62 | -313.53 | -798.31 |
|
Net Cash Inflow / Outflow
|
-11.28 | -105.52 | 29.88 | -145.00 | -392.41 |
Ratios
Profitability Ratios
| Kwality Pharma | Caplin Point Lab | Shilpa Medicare | Eris Lifesciences | Pfizer | |
|---|---|---|---|---|---|
|
ROCE (%)
|
24.01 | 24.97 | 11.43 | 14.47 | 23.39 |
|
ROE (%)
|
26.26 | 19.73 | 11.15 | 18.75 | 19.16 |
|
ROA (%)
|
15.59 | 18.69 | 7.80 | 9.26 | 14.95 |
|
EBIT Margin (%)
|
20.77 | 31.41 | 20.95 | 26.58 | 34.40 |
|
Net Margin (%)
|
14.55 | 28.10 | 16.19 | 20.60 | 26.88 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Kwality Pharma | Caplin Point Lab | Shilpa Medicare | Eris Lifesciences | Pfizer | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
37.94 | 15.01 | 27.91 | 9.59 | 10.69 |
|
EBIT Growth (%)
|
68.71 | 18.45 | 58.32 | 16.84 | 24.14 |
|
Net Profit Growth (%)
|
86.84 | 19.61 | 149.56 | 62.68 | -9.09 |
|
EPS Growth (%)
|
88.04 | 17.73 | -3.57 | 67.41 | 14.40 |
|
Book Value Growth (%)
|
25.66 | 26.75 | 9.67 | 36.71 | -0.34 |
Valuation Ratios
| Kwality Pharma | Caplin Point Lab | Shilpa Medicare | Eris Lifesciences | Pfizer | |
|---|---|---|---|---|---|
|
Price / Earnings
|
48.77 | 31.50 | 74.73 | 27.20 | 23.95 |
|
Price / Book Value
|
11.17 | 5.71 | 7.80 | 4.45 | 4.19 |
|
Dividend Yield (%)
|
0.00 | 0.29 | 0.06 | 0.00 | 1.86 |
|
EV/EBITDA
|
30.41 | 25.04 | 45.05 | 17.72 | 16.32 |
|
Market Cap (₹ Cr)
|
1,355.51 | 11,439.22 | 6,819.66 | 17,980.08 | 21,592.90 |
Solvency Ratios
| Kwality Pharma | Caplin Point Lab | Shilpa Medicare | Eris Lifesciences | Pfizer | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.09 | 0.00 | 0.07 | 0.24 | 0.00 |
|
Short term debt to equity ratio
|
0.26 | 0.00 | 0.16 | 0.12 | 0.00 |
|
Current Ratio
|
1.80 | 6.70 | 1.31 | 0.74 | 6.06 |
|
Quick Ratio
|
1.45 | 5.59 | 0.88 | 0.53 | 5.31 |
|
Interest Coverage
|
10.79 | 959.59 | 7.14 | 4.45 | 130.11 |
Operating Efficiency Ratios
| Kwality Pharma | Caplin Point Lab | Shilpa Medicare | Eris Lifesciences | Pfizer | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
50.55 | 36.10 | 30.84 | 21.07 | 7.07 |
|
Asset Turnover
|
1.07 | 0.63 | 0.48 | 0.45 | 0.52 |
|
Receivable days
|
157.57 | 121.68 | 113.81 | 63.88 | 26.06 |
|
Inventory Days
|
58.67 | 63.83 | 84.76 | 43.27 | 65.95 |
|
Payable days
|
160.16 | 108.28 | 101.94 | 151.85 | 81.01 |
|
Cash Conversion Cycle
|
56.07 | 77.23 | 96.62 | -44.70 | 11.00 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
